MRD assessments for CR/CRi patients
| CR/CRi, n = 97 . | MRD < 10−3 . | MRD ≥ 10−3 . | Nonevaluable . |
|---|---|---|---|
| n (%) | 28 (29) | 55 (57) | 14 (14) |
| DOR, mo | NR | 11.3 | 6.4 |
| OS, mo | NR | NR | 10.6 |
| CR/CRi, n = 97 . | MRD < 10−3 . | MRD ≥ 10−3 . | Nonevaluable . |
|---|---|---|---|
| n (%) | 28 (29) | 55 (57) | 14 (14) |
| DOR, mo | NR | 11.3 | 6.4 |
| OS, mo | NR | NR | 10.6 |
MRD assessments any time on therapy: after the initial dose, but before discontinuation of therapy (+7 days) or progressive disease, whichever came first.